SEARCH

SEARCH BY CITATION

References

  • 1
    Douillard JY, Cunningham D, Roth AD et al. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000; 355: 10417.
  • 2
    Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 2330.
  • 3
    Hotta T, Takifuji K, Arii K et al. Toxicity during l-LV/5FU adjuvant chemotherapy as a modified RPMI regimen for patients with colorectal cancer. Oncol Rep 2005; 14: 4339.
  • 4
    Peters GJ, van Groeningen CJ. Clinical relevance of biochemical modulation of 5-fluorouracil. Ann Oncol 1991; 2: 46980.
  • 5
    Peters GJ, Backus HH, Freemantle S et al. Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim Biophys Acta 2002; 1587: 194205.
  • 6
    Leichman CG. Thymidylate synthase as a predictor of response. Oncology (Williston Park). 1998; 12: 437.
  • 7
    Di Cresce C, Figueredo R, Ferguson PJ, Vincent MD, Koropatnick J. Combining small interfering RNAs targeting thymidylate synthase and thymidine kinase 1 or 2 sensitizes human tumor cells to 5-fluorodeoxyuridine and pemetrexed. J Pharmacol Exp Ther 2011; 338: 95263.
  • 8
    DeGregori J, Kowalik T, Nevins JR. Cellular targets for activation by the E2F1 transcription factor include DNA synthesis- and G1/S-regulatory genes. Mol Cell Biol 1995; 15: 421524.
  • 9
    Yamaguchi T, Yoshida T, Kurachi R et al. Identification of JTP-70902, a p15INK4b-inductive compound, as a novel MEK1/2 inhibitor. Cancer Sci 2007; 98: 180916.
  • 10
    Yamaguchi T, Kakefuda R, Tajima N, Sowa Y, Sakai T. Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo. Int J Oncol 2011; 39: 2331.
  • 11
    Gilmartin AG, Bleam MR, Groy A et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin Cancer Res 2011; 17: 9891000.
  • 12
    Flaherty KT, Robert C, Hersey P et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 2012; 367: 10714.
  • 13
    Sausville EA. Promises from trametinib in RAF active tumors. N Engl J Med 2012; 367: 1712.
  • 14
    Schoonjans K, Staels B, Auwerx J. The peroxisome proliferator activated receptors (PPARS) and their effects on lipid metabolism and adipocyte differentiation. Biochim Biophys Acta 1996; 1302: 93109.
  • 15
    Saidi SA, Holland CM, Charnock-Jones DS, Smith SK. In vitro and in vivo effects of the PPAR-alpha agonists fenofibrate and retinoic acid in endometrial cancer. Mol Cancer 2006; 5: 13.
  • 16
    Grabacka M, Plonka PM, Urbanska K, Reiss K. Peroxisome proliferator-activated receptor alpha activation decreases metastatic potential of melanoma cells in vitro via down-regulation of Akt. Clin Cancer Res 2006; 12: 302836.
  • 17
    Drukala J, Urbanska K, Wilk A et al. ROS accumulation and IGF-IR inhibition contribute to fenofibrate/PPARalpha-mediated inhibition of glioma cell motility in vitro. Mol Cancer 2010; 9: 159.
  • 18
    Lee JJ, Yu JY, Zhang WY et al. Inhibitory effect of fenofibrate on neointima hyperplasia via G(0)/G(1) arrest of cell proliferation. Eur J Pharmacol 2011; 650: 3429.
  • 19
    Yamasaki D, Kawabe N, Nakamura H et al. Fenofibrate suppresses growth of the human hepatocellular carcinoma cell via PPARalpha-independent mechanisms. Eur J Cell Biol 2011; 90: 65764.
  • 20
    Urbanska K, Pannizzo P, Grabacka M et al. Activation of PPARalpha inhibits IGF-I-mediated growth and survival responses in medulloblastoma cell lines. Int J Cancer 2008; 123: 101524.
  • 21
    Katayama K, Nakamura A, Sugimoto Y, Tsuruo T, Fujita N. FOXO transcription factor-dependent p15(INK4b) and p19(INK4d) expression. Oncogene 2008; 27: 167786.
  • 22
    Yuan J, Mehta PP, Yin MJ et al. PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity. Mol Cancer Ther 2011; 10: 218999.
  • 23
    Solit DB, Garraway LA, Pratilas CA et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006; 439: 35862.
  • 24
    Yeh JJ, Routh ED, Rubinas T et al. KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer. Mol Cancer Ther 2009; 8: 83443.
  • 25
    Jing J, Greshock J, Holbrook JD et al. Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212. Mol Cancer Ther 2012; 11: 7209.
  • 26
    Samuels Y, Wang Z, Bardelli A et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004; 304: 554.
  • 27
    Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006; 441: 42430.
  • 28
    Sakai T, Aoike A, Marui N, Kawai K, Nishino H, Fukushima M. Protection by cycloheximide against cytotoxicity induced by vincristine, colchicine, or delta 12-prostaglandin J2 on human osteosarcoma cells. Cancer Res 1989; 49: 11936.
  • 29
    Blagosklonny MV, Pardee AB. Exploiting cancer cell cycling for selective protection of normal cells. Cancer Res 2001; 61: 43015.
  • 30
    Takahara Y, Yogosawa S, Maruyama S et al. Lysocellin, a metabolite of the novel drug ‘alopestatin’, induces G1 arrest and prevents cytotoxicity induced by etoposide. Int J Oncol 2006; 28: 8239.
  • 31
    McDonald GT, Sullivan R, Pare GC, Graham CH. Inhibition of phosphatidylinositol 3-kinase promotes tumor cell resistance to chemotherapeutic agents via a mechanism involving delay in cell cycle progression. Exp Cell Res 2010; 316: 3197206.
  • 32
    Takagi K, Sowa Y, Cevik OM, Nakanishi R, Sakai T. CDK inhibitor enhances the sensitivity to 5-fluorouracil in colorectal cancer cells. Int J Oncol 2008; 32: 110510.
  • 33
    Infante JR, Fecher LA, Falchook GS et al. Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol 2012; 13: 77381.
  • 34
    Falchook GS, Lewis KD, Infante JR et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol 2012; 13: 7829.
  • 35
    Parsels LA, Parsels JD, Tai DC, Coughlin DJ, Maybaum J. 5-fluoro-2′-deoxyuridine-induced cdc25A accumulation correlates with premature mitotic entry and clonogenic death in human colon cancer cells. Cancer Res 2004; 64: 658894.
  • 36
    Wee S, Jagani Z, Xiang KX et al. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res 2009; 69: 428693.
  • 37
    Halilovic E, She QB, Ye Q et al. PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling. Cancer Res 2010; 70: 680414.
  • 38
    Zhu H, Guo W, Zhang L et al. Bcl-XL small interfering RNA suppresses the proliferation of 5-fluorouracil-resistant human colon cancer cells. Mol Cancer Ther 2005; 4: 4516.
  • 39
    Graidist P, Phongdara A, Fujise K. Antiapoptotic protein partners fortilin and MCL1 independently protect cells from 5-fluorouracil-induced cytotoxicity. J Biol Chem 2004; 279: 4086875.
  • 40
    Tumber A, Collins LS, Petersen KD et al. The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo. Cancer Chemother Pharmacol 2007; 60: 27583.
  • 41
    Lee JH, Park JH, Jung Y et al. Histone deacetylase inhibitor enhances 5-fluorouracil cytotoxicity by down-regulating thymidylate synthase in human cancer cells. Mol Cancer Ther 2006; 5: 308595.
  • 42
    Di Gennaro E, Bruzzese F, Pepe S et al. Modulation of thymidilate synthase and p53 expression by HDAC inhibitor vorinostat resulted in synergistic antitumor effect in combination with 5FU or raltitrexed. Cancer Biol Ther 2009; 8: 78291.
  • 43
    Noro R, Miyanaga A, Minegishi Y et al. Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and upregulation of p21(waf1/cip1) expression. Cancer Sci 2010; 101: 142430.
  • 44
    Matsuzaki T, Yashiro M, Kaizaki R et al. Synergistic antiproliferative effect of mTOR inhibitors in combination with 5-fluorouracil in scirrhous gastric cancer. Cancer Sci 2009; 100: 240210.
  • 45
    Lee KH, Hur HS, Im SA et al. RAD001 shows activity against gastric cancer cells and overcomes 5-FU resistance by downregulating thymidylate synthase. Cancer Lett 2010; 299: 228.
  • 46
    Perotti A, Locatelli A, Sessa C et al. Phase IB study of the mTOR inhibitor ridaforolimus with capecitabine. J Clin Oncol 2010; 28: 455461.
  • 47
    Choi EJ, Kim GH. 5-Fluorouracil combined with apigenin enhances anticancer activity through induction of apoptosis in human breast cancer MDA-MB-453 cells. Oncol Rep 2009; 22: 15337.
  • 48
    Xavier CP, Lima CF, Rohde M, Pereira-Wilson C. Quercetin enhances 5-fluorouracil-induced apoptosis in MSI colorectal cancer cells through p53 modulation. Cancer Chemother Pharmacol 2011; 68: 144957.
  • 49
    Qiao J, Gu C, Shang W et al. Effect of green tea on pharmacokinetics of 5-fluorouracil in rats and pharmacodynamics in human cell lines in vitro. Food Chem Toxicol 2011; 49: 14105.
  • 50
    Bertino JR, Banerjee D. Thymidylate synthase as an oncogene? Cancer Cell 2004; 5: 3012.
  • 51
    Edler D, Kressner U, Ragnhammar P et al. Immunohistochemically detected thymidylate synthase in colorectal cancer: an independent prognostic factor of survival. Clin Cancer Res 2000; 6: 48892.
  • 52
    Popat S, Matakidou A, Houlston RS. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 2004; 22: 52936.
  • 53
    Ohrling K, Edler D, Hallstrom M, Ragnhammar P, Blomgren H. Detection of thymidylate synthase expression in lymph node metastases of colorectal cancer can improve the prognostic information. J Clin Oncol 2005; 23: 562834.
  • 54
    Johnston PG, Lenz HJ, Leichman CG et al. Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res 1995; 55: 140712.
  • 55
    Lenz HJ, Hayashi K, Salonga D et al. p53 point mutations and thymidylate synthase messenger RNA levels in disseminated colorectal cancer: an analysis of response and survival. Clin Cancer Res 1998; 4: 124350.
  • 56
    Aschele C, Debernardis D, Casazza S et al. Immunohistochemical quantitation of thymidylate synthase expression in colorectal cancer metastases predicts for clinical outcome to fluorouracil-based chemotherapy. J Clin Oncol 1999; 17: 176070.
  • 57
    Wong NA, Brett L, Stewart M et al. Nuclear thymidylate synthase expression, p53 expression and 5FU response in colorectal carcinoma. Br J Cancer 2001; 85: 193743.
  • 58
    Bertino JR, Banerjee D. Is the measurement of thymidylate synthase to determine suitability for treatment with 5-fluoropyrimidines ready for prime time? Clin Cancer Res 2003; 9: 12359.